{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:40:06Z","timestamp":1786992006618,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005623","name":"Tokushima University","doi-asserted-by":"publisher","award":["24K02859"],"award-info":[{"award-number":["24K02859"]}],"id":[{"id":"10.13039\/501100005623","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jdiacomp.2025.108951","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T11:16:52Z","timestamp":1736594212000},"page":"108951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive treatment with dapagliflozin in elderly chronic kidney disease patients: Clinical efficacy and impact on body composition"],"prefix":"10.1016","volume":"39","author":[{"given":"Kazuhiro","family":"Nomura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naokazu","family":"Muramae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozue","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.108951_bb0005","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0010","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/CIRCRESAHA.111.261388","article-title":"Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence","volume":"111","author":"Wang","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s12325-023-02773-x","article-title":"Dapagliflozin utilization in chronic kidney disease and its real-world effectiveness among patients with lower levels of albuminuria in the USA and Japan","volume":"41","author":"Tangri","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0035","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/jdi.14054","article-title":"Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus","volume":"14","author":"Yoshimura","year":"2023","journal-title":"J of Diabetes Invest"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101620","article-title":"Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism","volume":"66","author":"Op Den Kamp","year":"2022","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/6470137","article-title":"Effect of Tofogliflozin on body composition and glycemic control in Japanese subjects with type 2 diabetes mellitus","volume":"2018","author":"Kamei","year":"2018","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0050","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jdi.13137","article-title":"Sodium\u2013glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: a case report","volume":"11","author":"Yasuda","year":"2020","journal-title":"J of Diabetes Invest"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0055","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/jdi.13306","article-title":"Japanese clinical practice guideline for diabetes 2019","volume":"11","author":"Araki","year":"2020","journal-title":"J of Diabetes Invest"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0065","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","article-title":"Asian working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment","volume":"21","author":"Chen","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1532-5415.2008.02126.x","article-title":"Added value of physical performance measures in predicting adverse health-related events: results from the health, aging and body composition study","volume":"57","author":"Cesari","year":"2009","journal-title":"J American Geriatrics Society"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0075","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0080","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/hep4.2069","article-title":"Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus","volume":"6","author":"Arai","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0085","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00228-023-03537-w","article-title":"Impact of tofogliflozin on hepatic outcomes: a systematic review","volume":"79","author":"Pathak","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0090","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109791","article-title":"Dapagliflozin for nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"185","author":"He","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0105","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/jdi.12985","article-title":"Ipragliflozin, a sodium\u2013glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial","volume":"10","author":"Inoue","year":"2019","journal-title":"J of Diabetes Invest"},{"key":"10.1016\/j.jdiacomp.2025.108951_bb0110","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.clnu.2023.10.004","article-title":"Sodium-glucose co-transporter 2 inhibitors and sarcopenia: a controversy that must be solved","volume":"42","author":"Afsar","year":"2023","journal-title":"Clin Nutr"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725000042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725000042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T20:09:46Z","timestamp":1740514186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725000042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1056872725000042"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.108951","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive treatment with dapagliflozin in elderly chronic kidney disease patients: Clinical efficacy and impact on body composition","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.108951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108951"}}